Every Form 4 that Oruka Therapeutics, Inc. (ORKA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ORKA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORKA filings page.
Oruka Therapeutics director Carl Dambkowski reported receiving 116,483 shares of common stock on January 23, 2026. The Form 4 shows the shares were acquired at a price of $0.00 through a transaction coded "J," which the footnote explains as a pro-rata distribution from a limited liability company in which he is a member. After this distribution, he beneficially owns 116,483 shares of Oruka common stock in direct form.
Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves reported option and warrant exercises followed by stock sales. On January 15, 2026, she exercised an employee stock option for 3,500 shares of common stock at $6.84 per share and an employee warrant for another 3,500 shares at $7.8 per share.
That same day, she sold 4,381 shares of common stock at a weighted average price of $31.5626 and 2,619 shares at a weighted average price of $32.237, all under a Rule 10b5-1 trading plan entered into on September 19, 2025. After these transactions, she directly owned 1,518 shares of common stock, as well as 221,563 employee stock options and 192,992 employee warrants.
Oruka Therapeutics, Inc. director Christopher Martin reported receiving stock options to purchase 35,000 shares of the company’s common stock at an exercise price of $30.21 per share on December 11, 2025.
The options expire on December 10, 2035 and vest in equal monthly installments, with 1/36 of the underlying shares vesting each month starting December 11, 2025. After this grant, he beneficially owns options for 35,000 shares, held directly.